We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 16, 2022

HRQoL Outcomes in Patients With Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Lancet Oncol 2022 Apr 27;[EPub Ahead of Print], R Motzer, C Porta, B Alekseev, SY Rha, TK Choueiri, MJ Mendez-Vidal, SH Hong, A Kapoor, JC Goh, M Eto, L Bennett, J Wang, JJ Pan, TL Saretsky, RF Perini, CS He, K Mody, D Cella

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading